Jeffrey Dierks Biography and Net Worth

Insider of Harmony Biosciences

Mr. Dierks is Chief Commercial Officer for Harmony Biosciences. Previously at Teva Pharmaceuticals, he held various leadership positions in Marketing, including Senior Director of US Pain Care, Sleep Disorders and Migraine Marketing. Prior to joining Teva, he held roles of increasing responsibility at several major pharmaceutical companies, including Janssen, Endo and Wyeth. Mr. Dierks has over 20 years of commercial experience, including several major product launches. He has led brand teams across numerous therapeutic areas, including CNS, Sleep Disorders, Pain Care and Migraine, as well as rare diseases.

He holds a bachelor’s degree from McDaniel College and a Master of Business Administration in marketing from the Temple Fox School of Business.

What is Jeffrey Dierks' net worth?: The estimated net worth of Jeffrey Dierks is at least $329,900.00 as of September 7th, 2021. Mr. Dierks owns 10,000 shares of Harmony Biosciences stock worth more than $329,900 as of March 25th. This net worth approximation does not reflect any other assets that Mr. Dierks may own. Learn More about Jeffrey Dierks' net worth.
How do I contact Jeffrey Dierks?: The corporate mailing address for Mr. Dierks and other Harmony Biosciences executives is 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462. Harmony Biosciences can also be reached via phone at 484-539-9800 and via email at lcaperelli@harmonybiosciences.com. Learn More on Jeffrey Dierks' contact information.
Has Jeffrey Dierks been buying or selling shares of Harmony Biosciences?: During the last ninety days, Jeffrey Dierks has sold $985,412.40 of Harmony Biosciences stock. Most recently, Jeffrey Dierks sold 1,629 shares of the business's stock in a transaction on Monday, January 27th. The shares were sold at an average price of $38.02, for a transaction totalling $61,934.58. Learn More on Jeffrey Dierks' trading history.
Who are Harmony Biosciences' active insiders?: Harmony Biosciences' insider roster includes Jeffrey Dayno (Insider), Jeffrey Dierks (Insider), John Jacobs (CEO), Sandip Kapadia (Chief Financial Officer and Chief Administrative Officer), and Andreas Wicki (Director). Learn More on Harmony Biosciences' active insiders.
Are insiders buying or selling shares of Harmony Biosciences?: In the last year, insiders at the sold shares 9 times. They sold a total of 94,148 shares worth more than $3,709,632.36. The most recent insider tranaction occured on January, 27th when insider Jeffrey Dierks sold 1,629 shares worth more than $61,934.58. Insiders at Harmony Biosciences own 30.8% of the company. Learn More about insider trades at Harmony Biosciences.
Information on this page was last updated on 1/27/2025.

Jeffrey Dierks Insider Trading History at Harmony Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/27/2025	Sell	1,629	$38.02	$61,934.58
1/24/2025	Sell	13,125	$37.31	$489,693.75
1/21/2025	Sell	1,123	$40.00	$44,920.00
1/15/2025	Sell	10,507	$37.01	$388,864.07
10/29/2024	Sell	21,496	$40.47	$869,943.12
9/27/2024	Sell	200	$40.05	$8,010.00
3/15/2024	Sell	11,979	$32.00	$383,328.00
3/8/2024	Sell	194	$32.00	$6,208.00
10/3/2022	Sell	12,173	$44.68	$543,889.64
8/22/2022	Sell	28,971	$47.00	$1,361,637.00
4/1/2022	Sell	14,471	$49.63	$718,195.73
11/1/2021	Sell	10,000	$41.67	$416,700.00
9/7/2021	Sell	5,000	$37.00	$185,000.00	10,000
6/15/2021	Sell	15,000	$31.32	$469,800.00	15,000

Jeffrey Dierks Buying and Selling Activity at Harmony Biosciences

Harmony Biosciences Company Overview

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Today's Range

Now: $32.99

$32.99

$34.59

50 Day Range

MA: $36.31

$32.18

$40.46

2 Week Range

Now: $32.99

$28.14

$41.61

Volume

1,042,867 shs

Average Volume

529,405 shs

Market Capitalization

$1.89 billion

P/E Ratio

15.64

Dividend Yield

N/A

Beta

0.82